Geovax Labs Inc (GOVX)

Overview News Price History Discussions Forecast Stock Split

Geovax Labs Inc stock is currently priced at $1.54, with a 24-hour trading volume of 31,949. It has seen a -0.65% decreased in the last 24 hours and a -21.83% declined in the past month. The chart indicates a potential bearish trend, as the stock is below the $1.57 pivot point. If it approaches the $1.47 support level, significant changes may occur.

Geovax Labs Inc Stock (GOVX) Financials Data

Geovax Labs Inc (GOVX) Revenue 2024

GOVX reported a revenue (TTM) of $356.60 thousand for the quarter ending March 31, 2022, a -70.72% decline year-over-year.

Geovax Labs Inc (GOVX) Net Income 2024

GOVX net income (TTM) was -$25.97 million for the quarter ending December 31, 2023, a -85.20% decrease year-over-year.

Geovax Labs Inc (GOVX) Cash Flow 2024

GOVX recorded a free cash flow (TTM) of -$25.22 million for the quarter ending December 31, 2023, a -31.61% decrease year-over-year.

Geovax Labs Inc (GOVX) Earnings per Share 2024

GOVX earnings per share (TTM) was -$14.29 for the quarter ending December 31, 2023, a -6.51% decline year-over-year.

Geovax Labs Inc Stock (GOVX) Latest News

GeoVax Announces 1-for-15 Reverse Stock Split to Regain Compliance with Nasdaq Minimum Bid Requirement

GlobeNewswire Inc.

GeoVax Appoints Dr. Marc Pipas as Executive Medical Director, Oncology

GlobeNewswire Inc.

GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; Centers for Disease Control and Prevention; U.S. Department of Defense; Emory University; University of Pittsburgh; EmVenio Research; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is based in Smyrna, Georgia.